利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

58 条记录 (耗时 0.036 秒)

    Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
    2.
    发明申请
    Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease 审中-公开
    脱髓鞘性粒细胞功能的治疗抑制作用

    公开(公告)号：US20130046015A1

    公开(公告)日：2013-02-21

    申请号：US13577579

    申请日：2011-02-11

    申请人： Robert C. Axtell ,  Lawrence Steinman

    发明人： Robert C. Axtell ,  Lawrence Steinman

    IPC分类号： A61K31/225 ,  A61P25/00 ,  A61P29/00

    CPC分类号： A61K31/225 ,  A61K31/18 ,  G01N33/6863 ,  G01N33/6896 ,  G01N2333/54 ,  G01N2800/285 ,  Y02A90/26

    摘要： Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment of IL-17-type inflammatory demyelinating disease and a pharmaceutically acceptable excipient are provided. Patients may be classified into subtypes prior to treatment, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.

    摘要翻译： 提供组合物和方法用于治疗IL-17型炎性脱髓鞘疾病与粒细胞功能抑制剂，例如， 弹性蛋白酶抑制剂。 感兴趣的疾病包括多发性硬化症，视神经脊髓炎，这种疾病的动物模型等。在一些实施方案中，提供了包含用于治疗IL-17型炎性脱髓鞘疾病的有效剂量的弹性蛋白酶抑制剂和药学上可接受的赋形剂的药物制剂。 患者可以在治疗之前分为亚型，哪些亚型对患者的治疗需求和对感兴趣的治疗的反应性是有益的。

    Markers for determination of patient responsiveness
    4.
    发明授权
    Markers for determination of patient responsiveness 有权
    确定患者反应性的标记

    公开(公告)号：US08828668B2

    公开(公告)日：2014-09-09

    申请号：US13026173

    申请日：2011-02-11

    申请人： Robert C. Axtell ,  Lawrence Steinman ,  May H. Han ,  Brigit A. de Jong ,  Chander Raman ,  Michael Walker ,  Jing Shi

    发明人： Robert C. Axtell ,  Lawrence Steinman ,  May H. Han ,  Brigit A. de Jong ,  Chander Raman ,  Michael Walker ,  Jing Shi

    IPC分类号： G01N33/53 ,  A61K39/395 ,  A61K38/00

    CPC分类号： A61K31/225 ,  A61K31/18 ,  G01N33/6863 ,  G01N33/6896 ,  G01N2333/54 ,  G01N2800/285 ,  Y02A90/26

    摘要： Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.

    摘要翻译： 提供组合物和方法用于炎性疾病的预后分类，例如 炎症性脱髓鞘疾病，患者进入亚型，哪些亚型对患者的治疗需求和对感兴趣的治疗的反应有信息。 细胞因子的模式提供了一种能够识别可能受益于治疗干预的患者的特征模式，并且将具有高反应概率的那些对治疗具有高反应能力的患者区分开来。 因此，这种签名模式的评估允许改进护理方法。 在本发明的一个实施方案中，自身免疫性疾病是多发性硬化症或神经性脊髓炎。

    Anthrose-based compositions and related methods
    5.
    发明申请
    Anthrose-based compositions and related methods 审中-公开
    基于Anthrose的组合物和相关方法

    公开(公告)号：US20150265691A1

    公开(公告)日：2015-09-24

    申请号：US11901234

    申请日：2007-09-14

    申请人： Denong Wang ,  Pavol Kovac ,  Lawrence Steinman ,  Gregory Carroll ,  Nicholas Turro ,  Jeffrey Koberstein ,  Rina Saksena ,  Roberto Adamo

    发明人： Denong Wang ,  Pavol Kovac ,  Lawrence Steinman ,  Gregory Carroll ,  Nicholas Turro ,  Jeffrey Koberstein ,  Rina Saksena ,  Roberto Adamo

    IPC分类号： A61K39/07 ,  G01N33/68 ,  G01N33/569 ,  A61K47/48 ,  C07K16/12 ,  C07K16/42

    CPC分类号： A61K39/07 ,  A61K47/61 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/55566 ,  A61K2039/6068 ,  A61K2039/6081 ,  C07K16/1278 ,  C12Q1/04 ,  G01N33/56911 ,  G01N2333/32 ,  G01N2469/10

    摘要： This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject and (ii) a pharmaceutically acceptable carrier. This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier. This invention provides a method for vaccinating a subject against Bacillus anthracis infection comprising administering to the subject a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in the subject and (ii) a pharmaceutically acceptable carrier, in an amount effective to stimulate production of antibodies to Bacillus anthracis spores in the subject, thereby vaccinating the subject against Bacillus anthracis.

    摘要翻译： 本发明提供了一种疫苗，其包含（i）含有量的含有糖的糖类，其量有效地增强受试者中对炭疽杆菌的免疫力，和（ii）药学上可接受的载体。 本发明提供了一种疫苗，其包含（i）含有含量的含糖的糖类的缀合物，其有效量以增强受试者中对炭疽芽孢杆菌的免疫力，其中所述含有所述含烟糖的糖通过接头与生物分子缀合，和（ii） 药学上可接受的载体。 本发明提供了一种针对炭疽芽孢杆菌感染接种受试者的方法，其包括向所述受试者施用疫苗，所述疫苗包含（i）含有有效量以提高受试者中对于炭疽杆菌的免疫力的含量的含有糖的糖类，以及（ii）药学上可接受的载体 ，其量有效地刺激在受试者中产生炭疽芽孢杆菌孢子的抗体，从而使受试者接种针对炭疽芽孢杆菌的疫苗。

    TRP/HIS exchange and kynurenin induced TRP transport
    7.
    发明授权
    TRP/HIS exchange and kynurenin induced TRP transport 有权
    TRP / HIS交换和kynurenin诱导TRP转运

    公开(公告)号：US08071744B2

    公开(公告)日：2011-12-06

    申请号：US13096643

    申请日：2011-04-28

    申请人： Thijs Kaper ,  Michael Platten ,  Lawrence Steinman ,  Wolf Frommer

    发明人： Thijs Kaper ,  Michael Platten ,  Lawrence Steinman ,  Wolf Frommer

    IPC分类号： C12N15/62

    CPC分类号： G01N33/6872 ,  G01N33/5008 ,  G01N2333/70596 ,  G01N2800/24

    摘要： The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.

    摘要翻译： 本发明提供了用于检测细胞中色氨酸浓度变化的方法以及鉴定调节细胞色氨酸浓度的试剂的方法。 特别地，本发明提供了检测色氨酸和犬尿氨酸之间的细胞交换的方法，以及用于鉴定调节该交换的试剂的方法。 本发明还提供了在有需要的受试者中治疗与免疫抑制相关的疾病的方法。 特别地，本发明涉及一种治疗与免疫抑制相关的疾病的方法，其包括将疾病与调节细胞Trp /犬尿苷交换的药物接触。 此外，本发明提供了鉴定调节免疫抑制的药剂的方法。

    TRP/HIS EXCHANGE AND KYNURENIN INDUCED TRP TRANSPORT
    8.
    发明申请
    TRP/HIS EXCHANGE AND KYNURENIN INDUCED TRP TRANSPORT 有权
    TRP /他的交换和KYNURENIN诱导TRP运输

    公开(公告)号：US20110223657A1

    公开(公告)日：2011-09-15

    申请号：US13096643

    申请日：2011-04-28

    申请人： Thijs Kaper ,  Michael Platten ,  Lawrence Steinman ,  Wolf Frommer

    发明人： Thijs Kaper ,  Michael Platten ,  Lawrence Steinman ,  Wolf Frommer

    IPC分类号： C07H21/00 ,  C12N15/63 ,  C12N5/10 ,  C12N1/00

    CPC分类号： G01N33/6872 ,  G01N33/5008 ,  G01N2333/70596 ,  G01N2800/24

    摘要： The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.

    摘要翻译： 本发明提供了用于检测细胞中色氨酸浓度变化的方法以及鉴定调节细胞色氨酸浓度的试剂的方法。 特别地，本发明提供了检测色氨酸和犬尿氨酸之间的细胞交换的方法，以及用于鉴定调节该交换的试剂的方法。 本发明还提供了在有需要的受试者中治疗与免疫抑制相关的疾病的方法。 特别地，本发明涉及一种治疗与免疫抑制相关的疾病的方法，其包括将疾病与调节细胞Trp /犬尿苷交换的药物接触。 此外，本发明提供了鉴定调节免疫抑制的药剂的方法。

    Alpha B-Crystallin as a therapy for inflammation
    9.
    发明申请
    Alpha B-Crystallin as a therapy for inflammation 有权
    Alpha B-Crystallin作为炎症治疗

    公开(公告)号：US20110160142A1

    公开(公告)日：2011-06-30

    申请号：US12931001

    申请日：2011-01-21

    申请人： Lawrence Steinman ,  Shalina Sheryl Ousman ,  William H. Robinson

    发明人： Lawrence Steinman ,  Shalina Sheryl Ousman ,  William H. Robinson

    IPC分类号： A61K38/17 ,  A61P25/28 ,  A61P29/00

    CPC分类号： A61K31/711 ,  A61K38/1709

    摘要： The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.

    摘要翻译： 本发明提供了通过向受试者施用有效量的提供αB-晶状蛋白活性的药剂来治疗炎性疾病的方法，其中剂量有效地抑制或预防疾病的起始，进展或复发，包括已建立的 疾病。 在一些实施方案中，本发明的方法包括向具有预先存在的炎症疾病状况的受试者施用有效量的α-B-晶状蛋白，以抑制或预防疾病的复发。